Investor relations
Dicot Pharma develops LIB-01 into a new potency drug that aims to become the first choice globally for the treatment of erectile dysfunction and premature ejaculation.
LIB-01 is in the clinical development phase, where a clinical phase 1 study was completed with very good results in Q2 2024. A phase 2a study is planned to start in the second half of 2024.
Development is intended to be carried out under own auspices up to and including clinical phase 2a and then together with major pharmaceutical companies to introduce LIB-01 to the world market.
Dicot Pharma's share is listed on Spotlight Stock Market and the company has approximately 6,500 shareholders.